leadf
logo-loader
viewOragenics Inc
(
NYSE:OGEN
)

Oragenics making 'great progress' enrolling patients in oral mucositis clinical trial

Oragenics (NYSE:OGEN) CEO Alan Joslyn caught up with Proactive at the BIO Investor Forum in San Francisco. 

Joslyn says Oragenics is making 'great progress' enrolling patients in oral mucositis clinical trial. Oral mucositis is a painful side effect in patients who are receiving chemotherapy in head and neck cancers.

Quick facts: Oragenics Inc

Follow
NYSE:OGEN

Price: 0.6264 USD

Market Cap: $72.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Delta 9 Cannabis hit top 10 of Globe and Mail's Top Growth companies survey

Delta 9 Cannabis CEO John Arbuthnot joined Steve Darling from Proactive to share news the company finished 7th in the Globe and Mail’s 3rd Annual Top Company growth survey with 448 entrants based on 3-year growth. Delta 9 saw an increase of revenue over 3 years of 5,413 percent. Arbuthnot...

1 hour, 55 minutes ago

2 min read